Role of the serotonin transporter in pulmonary arterial hypertension

Yvonne Dempsie, Margaret R MacLean

Research output: Contribution to journalLiterature review

Abstract

Pulmonary arterial hypertension is a disease in which pulmonary arterial pressure is raised, leading to right heart failure. Survival is poor despite current therapeutic strategies. The 'serotonin hypothesis of pulmonary arterial hypertension' arose in the 1960s following an 'epidemic' of pulmonary arterial hypertension in women taking the indirect serotinergic agonist aminorex as an anorexigen. In the 1980s, the hypothesis was revisited following the occurrence of pulmonary arterial hypertension associated with the use of fenfluramines as anorexigens; these are also indirect serotinergic agents. Research has identified changes in serotonin synthesis, serotonin receptor activation and serotonin uptake via the serotonin transporter in experimental and clinical pulmonary arterial hypertension. This review will discuss our current understanding of this serotonin hypothesis with particular reference to the role of the serotonin transporter.
Original languageEnglish
Pages (from-to)749-57
Number of pages9
JournalExpert Review of Clinical Pharmacology
Volume1
Issue number6
DOIs
Publication statusPublished - Nov 2008

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Pulmonary Hypertension
Serotonin
Aminorex
Fenfluramine
Serotonin Receptors
Arterial Pressure
Heart Failure
Lung
Survival
Research

Keywords

  • serotonin transporter
  • pulmonary arterial hypertension
  • agonist

Cite this

@article{ce212d6e75ec47f195458738ee468a8a,
title = "Role of the serotonin transporter in pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension is a disease in which pulmonary arterial pressure is raised, leading to right heart failure. Survival is poor despite current therapeutic strategies. The 'serotonin hypothesis of pulmonary arterial hypertension' arose in the 1960s following an 'epidemic' of pulmonary arterial hypertension in women taking the indirect serotinergic agonist aminorex as an anorexigen. In the 1980s, the hypothesis was revisited following the occurrence of pulmonary arterial hypertension associated with the use of fenfluramines as anorexigens; these are also indirect serotinergic agents. Research has identified changes in serotonin synthesis, serotonin receptor activation and serotonin uptake via the serotonin transporter in experimental and clinical pulmonary arterial hypertension. This review will discuss our current understanding of this serotonin hypothesis with particular reference to the role of the serotonin transporter.",
keywords = "serotonin transporter, pulmonary arterial hypertension, agonist",
author = "Yvonne Dempsie and MacLean, {Margaret R}",
year = "2008",
month = "11",
doi = "10.1586/17512433.1.6.749",
language = "English",
volume = "1",
pages = "749--57",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Taylor & Francis Group",
number = "6",

}

Role of the serotonin transporter in pulmonary arterial hypertension. / Dempsie, Yvonne; MacLean, Margaret R.

In: Expert Review of Clinical Pharmacology, Vol. 1, No. 6, 11.2008, p. 749-57.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - Role of the serotonin transporter in pulmonary arterial hypertension

AU - Dempsie, Yvonne

AU - MacLean, Margaret R

PY - 2008/11

Y1 - 2008/11

N2 - Pulmonary arterial hypertension is a disease in which pulmonary arterial pressure is raised, leading to right heart failure. Survival is poor despite current therapeutic strategies. The 'serotonin hypothesis of pulmonary arterial hypertension' arose in the 1960s following an 'epidemic' of pulmonary arterial hypertension in women taking the indirect serotinergic agonist aminorex as an anorexigen. In the 1980s, the hypothesis was revisited following the occurrence of pulmonary arterial hypertension associated with the use of fenfluramines as anorexigens; these are also indirect serotinergic agents. Research has identified changes in serotonin synthesis, serotonin receptor activation and serotonin uptake via the serotonin transporter in experimental and clinical pulmonary arterial hypertension. This review will discuss our current understanding of this serotonin hypothesis with particular reference to the role of the serotonin transporter.

AB - Pulmonary arterial hypertension is a disease in which pulmonary arterial pressure is raised, leading to right heart failure. Survival is poor despite current therapeutic strategies. The 'serotonin hypothesis of pulmonary arterial hypertension' arose in the 1960s following an 'epidemic' of pulmonary arterial hypertension in women taking the indirect serotinergic agonist aminorex as an anorexigen. In the 1980s, the hypothesis was revisited following the occurrence of pulmonary arterial hypertension associated with the use of fenfluramines as anorexigens; these are also indirect serotinergic agents. Research has identified changes in serotonin synthesis, serotonin receptor activation and serotonin uptake via the serotonin transporter in experimental and clinical pulmonary arterial hypertension. This review will discuss our current understanding of this serotonin hypothesis with particular reference to the role of the serotonin transporter.

KW - serotonin transporter

KW - pulmonary arterial hypertension

KW - agonist

U2 - 10.1586/17512433.1.6.749

DO - 10.1586/17512433.1.6.749

M3 - Literature review

VL - 1

SP - 749

EP - 757

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 6

ER -